Compliance
DOL Issues Final PBM Fee-Disclosure Rule: What Plan Sponsors Need to Know
November 17, 2026
Pharmacy benefit managers (PBMs) play a significant role in managing prescription drug benefits, including negotiating drug pricing and manufacturer rebates. On October 29, 2026, the U.S. Department of Labor (DOL) issued a final rule requiring PBMs to provide greater transparency into how they are compensated when serving certain self-insured group health plans. The rule implements an April 2025 executive order on drug-price transparency and establishes new obligations that enable plan fiduciaries to evaluate whether PBM compensation is reasonable, a core requirement under ERISA.
The rule applies to PBMs and affiliated brokers and consultants serving large, ERISA-covered self-insured health plans, generally those with 100 or more employees. Fully insured plans are outside this rule; the DOL has reserved separate disclosure requirements for those plans for future rulemaking.
The final rule takes effect January 4, 2027, with its detailed PBM disclosure and related requirements applying to plan years beginning on or after July 1, 2027. During the transition, the DOL has established a temporary enforcement policy to give plan sponsors and PBMs time to develop compliance mechanisms. Separate PBM requirements under the Consolidated Appropriations Act (CAA), 2026 apply to plan years beginning on or after August 3, 2028.
Two Timelines to Watch
The DOL’s final rule and the CAA, 2026 have different compliance timelines. Although the CAA, 2026 includes overlapping PBM requirements that apply to plan years beginning on or after August 3, 2028, the DOL chose not to delay its final rule to align with that date. The DOL explained that doing so would unnecessarily delay greater transparency in PBM contracting. The result is a two-track timeline:
- The DOL’s detailed disclosure requirements apply to plan years beginning on or after July 1, 2027.
- Additional CAA, 2026 requirements apply to plan years beginning on or after August 3, 2028.
What PBMs Must Disclose
The requirements address both what PBMs must disclose at the outset of a contract and the information they must provide on an ongoing basis.
Initial Disclosures
Before entering into, extending, or renewing a service contract, PBMs must provide written initial disclosures to plan fiduciaries. For renewals and extensions, the disclosure must be provided at least 90 days in advance. Key disclosure requirements include:
- Services: A description of the PBM services to be performed
- Direct compensation: Amounts the PBM expects to receive directly from the plan, itemized by service
- Indirect compensation: Compensation from sources other than the plan to include manufacturer rebates, spread pricing, pharmacy recoupments, and price protection agreements
- Drug pricing methodology: The net price payable for drugs after rebates and fees, or the methodology used to calculate it if an exact amount cannot be determined
- Formulary placement incentives: Manufacturer arrangements that influence drug placement on the formulary and their impact on the plan
- Termination compensation: Any compensation tied to contract termination, including how prepaid amounts are calculated and refunded
- Audit rights statement: A written statement explaining the plan’s right to audit PBM disclosures
Ongoing Disclosures
After the initial disclosure, PBMs must provide ongoing disclosures twice a year or quarterly if the plan requests it. These disclosures cover the same compensation categories. If any ongoing amount exceeds the originally disclosed figure by 5% or more, the PBM must provide a written explanation identifying the overage and its cause. This allows fiduciaries to monitor whether PBM compensation remains reasonable over the life of the contract.
Plan Audit Rights
The final rule gives group health plans the right to audit their PBM at least once per year. Plans may independently select their auditor. PBMs cannot restrict that choice, limit the timing or location of the audit, or restrict access to information. PBMs must:
- Acknowledge an audit request within 10 business days
- Generally, provide required audit information within 60 calendar days
Connection to the CAA, 2026
The CAA, 2026, signed February 3, 2026, adds another layer of PBM requirements for plan years beginning on or after August 3, 2028. These include PBMs providing more detailed drug-spending data to group health plans, and plans providing participants and beneficiaries with annual notices about PBM reporting requirements. Significantly, the CAA also requires PBMs to pass 100% of rebates, fees, and alternative discounts and other remuneration from drug manufacturers directly to group health plans as a condition of the PBM’s contracts.
Employer Takeaways
Employers can take several steps now to prepare for the new requirements and strengthen their oversight of PBM arrangements:
- Review your current arrangements. Review your PBM contracts and disclosure practices now to assess whether your PBM is prepared to meet the new disclosure standards.
- Strengthen fiduciary oversight. Use PBM disclosures to assess whether compensation is reasonable as part of your ERISA fiduciary review. Document your review process.
- Negotiate audit provisions. The final rule grants plans the right to audit their PBM at least once per year. Build audit provisions into upcoming PBM contract negotiations, including auditor selection and information-access rights.
- Prepare for the 2028 CAA requirements. CAA rebate pass-through and reporting requirements apply to plan years beginning on or after August 3, 2028. Work with your benefits consultant to prepare for both sets of obligations.
- Address missing disclosures. If your PBM fails to provide required information, follow the rule’s correction and DOL-notification procedures. Following these procedures may help protect the plan fiduciary from prohibited-transaction liability arising from the PBM’s disclosure failure.
If you have questions, please reach out to your Hylant representative for further information. Don’t have one? Contact us here.
The above information does not constitute advice. Always contact your employee benefits broker or trusted advisor for insurance-related questions.
Authored by
With more than 32 years of industry experience, Lorenna helps clients understand and keep abreast of complex healthcare plan requirements and the ever-changing regulatory environment. She supports both clients and Hylant teams by delivering tailored communication materials, hosting seminars, and providing strategic insights that empower exceptional service delivery.